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Abstract
Influenza A viruses belong to the best studied viruses, however no effective prevention against influenza infection
has been developed. The emerging of still new escape variants of influenza A viruses causing epidemics and peri-
odic worldwide pandemics represents a threat for human population. Therefore, current, hot task of influenza virus
research is to look for a way how to get us closer to a universal vaccine. Combination of chosen conserved anti-
gens inducing cross-protective antibody response with epitopes activating also cross-protective cytotoxic T-cells
would offer an attractive strategy for improving protection against drift variants of seasonal influenza viruses and
reduces the impact of future pandemic strains. Antigenically conserved fusion-active subunit of hemagglutinin
(HA2 gp) and ectodomain of matrix protein 2 (eM2) are promising candidates for preparation of broadly protective
HA2- or eM2-based vaccine that may aid in pandemic preparedness. Overall protective effect could be achieved by
contribution of epitopes recognized by cytotoxic T-lymphocytes (CTL) that have been studied extensively to reach
much broader control of influenza infection. In this review we present the state-of-art in this field. We describe
known adaptive immune mechanisms mediated by influenza specific B- and T-cells involved in the anti-influenza
immune defense together with the contribution of innate immunity. We discuss the mechanisms of neutralization
of influenza infection mediated by antibodies, the role of CTL in viral elimination and new approaches to develop
epitope based vaccine inducing cross-protective influenza virus-specific immune response.
1. Introduction
Influenza remains a serious respiratory disease in spite
of the availability of antivirals and inactivated trivalent
vaccines, which are effective for most recipients. Influ-
enza viruses are RNA viruses with strongly immuno-
genic surface proteins, especially the hemagglutinin.
Error-prone RNA-dependent RNA polymerase and seg-
mented genome enable influenza viruses to undergo
minor (antigenic drift) as well as major (antigenic shift)
antigenic changes, which permit the virus to evade
adaptive immune response in a variety of mammalian
and avian species, including humans. The unpredictable
variability of influenza A viruses, which cause yearly epi-
demics in human population, is the main reason why no
effective prevention against influenza infection exists up
to date. Currently available vaccines induce antibodies
against seasonal and closely related antigenic viral
strains, but do not protect against antibody-escape var-
iants of seasonal or novel influenza A viruses. Therefore,
there is a call for development of a vaccine, which
would be protective against virus strains of different HA
subtypes and would not need to be updated every year.
New approach to prepare a universal vaccine lies in the
selection of conserved epitopes or proteins of influenza
A virus, which induce cross-protective immune
response, particularly M2, HA2, M1, NP [1-3].
2. Induction of adaptive immunity by influenza
infection
Influenza infection induces specific humoral immunity
represented by systemic and local antibody response, as
well as cellular immunity, represented by specific T-cell
response (Figure 1). Both of them are important in the
host defense against influenza infection, because of
their close cooperation mediated by various immune
mechanisms. Dendritic cells and macrophages (antigen
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ing and driving of adaptive immune response [4]. Exo-
genous viral antigens, including inactive viral particles,
intact viruses or infected cells, are taken up by APCs
through endocytosis or phagocytosis. Their further pro-
cessing results in generation of peptides that are pre-
sented via MHC I or MHC II molecules to CD8+
precursor T-cell and CD4+ helper T-cell precursors
(Th0), respectively. Th0 cells are subdivided to Th1-
and Th2-type helper cells, based on the cytokine profiles
they produce. Following influenza infection, APCs
secrete IL-12 that contributes to the differentiation of
Th0 into Th1 cells, which secrete IFN-g and help to
produce IgG2a antibodies [5,6]. Th1 cells also produce
IL-2, required for the proliferation of the virus-specific
CD8+ CTLs. In contrast, when IL-10 is present early in
Figure 1 Humoral and cellular immunity induced by influenza virus infection. (1) Influenza virus binds to the receptor on the host cell and
entry the cell by receptor-mediated endocytosis. (2) The endosomal acidification permits fusion of the host and viral membranes by altering the
conformation of hemagglutinin. (3) Upon the fusion, viral ribonucleoprotein complexes (RNP complex) are released into the cytoplasm and
(4) transported to the nucleus, where the viral RNAs (vRNA) are transcribed into messenger RNAs (mRNA) and replicated by the viral RNA-
dependent RNA polymerase complex into complementary RNA (cRNA). (5) mRNA are exported to the cytoplasm for translation of structural
proteins. (6) Synthesis of envelope proteins take place on ribosomes of endoplasmic reticulum. (7) The newly synthesized viral RNPs are
exported from the nucleus to the assembly site at the apical plasma membrane, where (8) new virus particles are budding and release out of
host cells. Influenza virus infection triggers innate (not shown) and adaptive immune response where the effector cells and molecules are
involved in restriction of viral spread, as follows: The cellular immune response (right) is initiated after recognition of viral antigens presented via
MHCI and MHC II molecules by antigen presenting cells (APC), which then leads to activation, proliferation and differentiation of antigen-specific
CD8+ T or CD4+ cells. These cells gain effector cell function and either they help directly (Th1 or Th2 cell) to produce antibodies or, CTL effector
cells recognize antigen peptides presented by MHCI on APC and kill the virus infected cells by exocytosis of cytolytic granules. The humoral
immune response (left)is mediated by specific antibodies (e.g IgG, IgA) produced by antibody secreting plasma cells (ASC) which are the final
stage of B cell development. This process is aided by CD4+ T helper and T cell-derived cytokines essential for the activation and differentiation
of both B-cell responses and CD8+ T cell responses.
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cells, which secrete IL-4, IL-5, IL-6 and help preferen-
tially drive IgG1, IgA and IgE Ab production by anti-
body-secreting plasma cells (ASCs) [6-9]. CD8+
precursor T-cells, which maturate into CTLs (cytotoxic
T lymphocytes), release antiviral cytokines (IFN-g)u p o n
recognition of short viral peptides presented by MHC I
molecules on virus-infected epithelial cells, and destroy
the virus infected cells by exocytosis of cytolytic gran-
ules. The granules contain cytolytic protein perforin and
granzymes. Perforin is a protein that creates pores in
membranes of infected cells. Granzymes are members of
serine protease family. In the presence of perforin, gran-
zymes enter into the cytoplasm of infected cells and
initiate proteolysis, which triggers destruction of the tar-
get cell [10,11]. CTLs could mediate killing of infected
cells also by perforin-independent mechanisms of cyto-
toxicity. This involves binding of Fas receptor in the
infected target cell membranes with the Fas ligand
(FasL) expressed on activated CTLs. Interaction of FasL
with corresponding Fas receptor leads to the activation
of caspases, which induce apoptosis in influenza infected
cells [12-14].
Unlike T-cells, which recognize linear epitopes pre-
sented by MHC molecules, B cells can recognize antigen
in its native form. Antibody response against influenza
infection is mediated by secretory IgA antibodies and
serum IgG antibodies. IgA are transported across the
mucosal epithelium of the upper respiratory tract, where
they represent the first immunobarrier to influenza
viruses. IgG transude from the serum to the mucus by
diffusion and are primarily responsible for the protec-
tion of the lower respiratory tract [15].
3. Protection against influenza infection mediated
by antibodies
Specific antibodies induced by influenza virus infection
can neutralize infection by several different mechanisms
(Figure 2). They can directly block virus attachment to
the target cells by interfering with virus-receptor inter-
action and thus prevent influenza infection (Figure 2A).
These antibodies are directed to the globular domain of
the surface antigen, hemagglutinin [16]. However,
because of high variability of influenza A viruses, neu-
tralization activity of these Abs is limited to viral strains,
which are antigenically similar to the inducers of Ab
Figure 2 Mechanisms of antibody-mediated neutralization during influenza infection. A. Serum IgG or B. mucosal IgA antibodies specific
to hemagglutinin prevent influenza infection by blocking attachment to host cell receptors. C. After binding, the virus is internalized by receptor
mediated endocytosis. The low pH in the endosome triggers conformational changes in hemagglutinin that expose fusion peptide located in
HA2 required for membrane fusion. In this step, antibodies bound to HA2 block the fusion of viral and endosomal membranes and prevent
release of ribonucleoprotein complex into the cytoplasm of target cell. D. Intracellular neutralization of influenza virus through transcytotic
pathway of IgA that complex with viral proteins and inhibit assembly of progeny virions. E. Antibodies specific to neuraminidase inhibit release
of budding viral particles and further spread of influenza infection by inhibition of neuraminidase activity.
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immunity mediated by secreted form of IgA Abs in the
upper respiratory tract is more cross-protective against
heterologous virus infection than systemic immunity
mediated by IgG Abs [17,18]. The strong cross-protec-
tive potential of IgA Abs appears to be the consequence
of their polymeric nature, resulting in higher avidity of
Abs for the influenza virus compared to the monomeric
serum IgG Abs [18]. After synthesis by ASC, dimeric
IgA (dIgA) Abs bind to the polymeric immunoglobulin
receptor expressed on the basolateral surface of the
epithelial cells and are transcytosed to the apical surface,
where the poly-Ig receptor is cleaved, secretory IgA are
released and prevent infection by blocking attachment
to the epithelial cells (Figure 2B). Moreover, dIgA Abs
a r ea b l et ob i n dt ot h en e w l ys y n t h e s i z e dv i r a lp r o t e i n s
within infected cells, thus preventing virion assembly
(Figure 2D) [19].
After attachment to the receptor on the target cell,
influenza virus is internalized by receptor-mediated
endocytosis. Conformational changes of hemagglutinin
triggered by the low pH in the endosome activate viral
and endosomal membrane fusion. In this step, antibo-
dies, which bind to the non-receptor binding region of
HA, could interfere with the low-pH induced conforma-
tional change in the HA molecule required for the
fusion. Inhibition of the fusion between viral and endo-
somal membrane proteins mediated by such antibodies
prevents release of the ribonucleoprotein complex (RNP
complex) into the cytoplasm of the target cell, resulting
in the inhibition of viral replication (Figure 2C) [20,21].
In the last step of influenza infection, antibodies specific
to the neuraminidase (NA) can bind to budding virus
and prevent release of virions from the infected cells.
Anti-NA antibodies cause aggregation of virus particles
what consequently leads to the reduction of the effective
number of infectious units (Figure 2E) [22]. Understand-
ing the processes of antibody-mediated neutralization
confers valuable insights into virus-cell interactions and
helps to design potent vaccines.
Recent studies demonstrate that there are also other
antibody-mediated mechanisms by which cells infected
with influenza virus can be cleared. Antibodies, after
coating the infected cells or viral particles, could induce
elimination of the virus by FcR-mediated phagocytosis
[23] and mediate killing of infected cells via antibody-
dependent cell-mediated cytotoxicity (ADCC) or com-
plement-dependent cytotoxicity (CDC) (Figure 3)
[24,25]. In the case of ADCC, Fc receptor-bearing nat-
ural killer cells (NK cells) recognize Fc region of anti-
body-coated infected cells and destroy them by releasing
cytotoxic granules containing perforins and granzymes,
thus limiting the spread of infection [24]. Opsonization
of infected cells or free viral particles by specific
antibodies could lead to FcR-mediated phagocytosis and
subsequent inactivation of the virus in an intracellular
compartment of the macrophage [23]. Alternatively, Fc
regions of antibodies bound to the surface of infected
cells may contribute to the clearance of influenza infec-
tion by the activation of classical complement pathway.
The interaction of opsonic complement proteins with
complement receptor on macrophages (CR) increases
the rate of phagocytosis of macrophages, causing direct
virolysis or improvement of antibody-mediated inhibi-
tion of virus attachment to host cells [26,27]. However,
contribution of complement to the protective capacity
of antibodies is contradictory, since it was shown that
passive transfer of murine polyclonal anti-eM2 serum
into C3-negative mice had protective effect [24], while
human monoclonal anti-M2 antibodies could not pro-
tect complement-depleted mice [25]. It should be
noticed that though some antibodies directed to con-
served antigens such as M2 do not prevent infection by
direct binding to virus, they can contribute to an earlier
recovery from the infection by indirect antibody-
mediated mechanisms after binding to Fc-receptors on
macrophages or NK cells. It is possible that the same
mechanism of protection is mediated by antibodies to
HA2 glycopolypeptide (HA2 gp), a conserved part of
HA. They also do not prevent infection, but their strong
protective potential has been proved in vivo [28-31]. For
this reason understanding the role of the Fc effector
function of antibodies in the clearance of influenza
infection is required.
4. Conserved antigens of influenza virus as
inductors of cross-protective humoral immunity
Both, ectodomain of M2 and HA2 gp are conserved
antigens inducing antibodies protecting against influenza
infection. Therefore, various studies are focused on
these two antigens as inductors of heterosubtypic anti-
body response.
4.1 Ectodomain of M2 protein
M2 protein is a single-pass type III membrane protein
forming homotetramers representing pH-gated proton
channel incorporated into the viral lipid envelope. This
proton channel is essential for efficient release of viral
genome during viral entry [32]. M2 protein is abun-
dantly expressed at the apical plasma membrane of
infected epithelial cells, but only a small number (16-20
molecules/virion) of M2 molecules are incorporated into
virions [33,34]. Great attention is paid to the extracellu-
lar N-terminal domain of M2 protein (eM2), a 23 amino
acid peptide, which is highly conserved in all human
influenza A strains. It is therefore an attractive target
for preparation of a universal influenza A vaccine. In
contrast to hemagglutinin and neuraminidase, eM2 is a
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increase its immunogenicity were used. All of them are
based on increasing the immunogenicity of small anti-
gen molecules by insertion of their multiple copies into
a suitable immunogen Neiryn c ke ta l[ 3 6 ]p r e p a r e da
fusion protein composed of eM2 and hepatitis B virus
core (HBc) protein. This fusion protein has the ability to
aggregate into the highly immunogenic virus-like parti-
cles inducing a long-lasting protection against lethal
influenza A infection. High in vivo protective effect of
described virus-like particles was proven after intraperi-
toneal or intranasal immunization of mice and subse-
quent infection with lethal dose of influenza viruses of
various HA subtypes [37]. Efficacy of these particles has
been increased by application of new adjuvant CTA1-
DD. Combination of the eM2-HBc construct with the
new adjuvant led to the protection of mice against lethal
infection and a remarkably lower morbidity [38]. Var-
ious constructs of eM2 peptide engineered by conjuga-
tion to carrier proteins were evaluated as a vaccine,
which successfully protected animals against infection
with homologous but also heterologous human strains
[24,36,37,39-42].
A different approach to increase immunogenicity of
eM2 was described by other groups. Constructs com-
posed of four tandem copies of the eM2 peptide fused
to flagellin, a ligand of TLR5 (Toll-like receptor 5) [41],
or glutathione-S-transferase fusion protein bearing var-
ious numbers of eM2 epitope copies [42], were used as
immunogens. These studies showed that high eM2 epi-
tope densities in a single recombinant protein molecule
resulted in enhanced eM2-specific humoral response
and higher survival rates of infected animals.
Another way to stimulate the immune system by small
peptide was described by Ernst et al. [39]. They fused
the target antigen with hydrophobic protein domain
(HD). Such fusion protein can be effectively built into
the membrane of small unilamelar liposomes, usually
with a diameter of about 100 nm. Ernst et al. [39] pre-
pared liposomes with incorporated recombinant fusion
protein eM2-HD comprising three distant aminoacid
sequences of eM2 of potentially pandemic strains.
Figure 3 Indirect anti-influenza mechanisms of protection via Fc region of antibodies. Infected cells are killed via antibody-dependent cell-
mediated cytotoxicity (ADCC) after activation of natural killer cells (NK cell) by Fc region of IgG (red arrow). Phagocytosis of viral particles or
infected cells (not shown) is mediated through recognition of Fc region of IgG by macrophages (green arrows) or by interaction of complement
with complement receptor on macrophages (CR) (blue arrow).
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was protective against influenza virus strains of various
subtypes and stimulated the production of specific IgG1
antibodies in mouse sera. Moreover, mice passively
immunized with these antibodies were protected against
lethal infection.
M2 protein in its native state forms a homotetramer,
comprising also conformational epitopes, which might
play important role in eM2 immunogenicity. It was
shown that oligomer-specific antibodies were induced
by recombinant eM2 protein mimicking the natural
quaternary structure of M2 ectodomain in viral particle
[43]. For this purpose, a modified version of leucine zip-
per from yeast transcription factor GCN4 was bound to
eM2. High titers of antibodies recognizing M2 protein
in the native conformation were obtained after intraperi-
toneal or intranasal immunization with this recombinant
protein, and immunized micew e r ef u l l yp r o t e c t e d
against lethal dose of influenza A virus [43]. Such
vaccine could improve quality of humoral immune
response with antibodies elicited not only against linear
epitopes but also against conformational epitopes.
Above described results indicate that eM2 is a valid
and versatile vaccine candidate to induce protective
immunity against any strain of human influenza A
viruses, and give a promise for finding new “universal”
vaccine against flu.
4.2 Conserved epitopes of hemagglutinin
Hemagglutinin (HA) is the major influenza virus target
antigen recognized by neutralizing antibodies. It is a sur-
face glycoprotein, synthesized as a single polypeptide,
which is trimerized. Each monomer of HA is synthe-
sized as a precursor molecule HA0 post-translationally
cleaved by host proteases into two subunits, HA1 and
HA2 linked by a single disulfide bond [16]. Cleavage
into HA1 and HA2 gp is essential for the infectivity of
the virus particle and spread of the infection in the host
organism [44].
T h eH A 1o fi n f l u e n z aAv i r u sf o r m sam e m b r a n e -
distal globular domain that contains the receptor-
binding site and most antigenic sites recognized by
virus-neutralizing antibodies preventing attachment of
virus to the host cell. Escape variants with mutation in
the antigenic site easily avoid neutralization by existing
host antibodies, leading to seasonal influenza outbreaks
[45]. In spite of continual antigenic changes of hemag-
glutinin, common epitopes shared by various strains
were identified. Although the degree of sequence diver-
sity between HA subtypes is great, particularly in the
HA1 glycopolypeptides, HA2 is its rather conserved
part. According to documented results, HA2 has the
prerequisite to be one of the potential inductors of pro-
tective heterosubtypic immunity [1,28,29,46-48]. HA2
represents the smaller C-terminal portion of hemaggluti-
nin, which forms a stem-like structure that mediates the
anchoring of the globular domain to the cellular or viral
membrane. N-terminal part of HA2 gp, termed the
fusion peptide, plays a substantial role in the fusion
activity of influenza virus. It was demonstrated that the
rearrangements of HA as well as the fusion process is
temperature- and pH-dependent [49,50]. At neutral pH,
the N-terminus of the fusion peptide is inserted into the
inter-space of HA trimer. At low pH, which triggers the
fusion process, N-terminus of the fusion peptide is
exposed and inserted into the target membrane, allow-
ing the release of the ribonucleoprotein complex into
the cytoplasm [51,16]. Although the epitopes of the
HA2 gp are less accessible for interaction with antibo-
dies in native virus than those of HA1 gp, HA2-specific
antibodies are induced during natural infection in
humans [52] as well as in mice [53]. Significance of
HA2-specific antibodies for the heterosubtypic immunity
lies in their broad cross-reactivity [1,31,48,54,55]. While
HA2-specific antibodies do not act by obstructing the
binding of the virus to the host cells [56-58] it should
be emphasized that HA2-specific antibodies are able to
reduce the replication of influenza viruses of various HA
subtypes by several ways: binding of antibody can inhibit
the fusion of viral and endosomal membranes [59,60] by
preventing the conformation change of HA induced by
low pH [20,21,61] or by blocking the insertion of the
fusion peptide into the endosomal membrane [62,63].
Moreover, it was shown that passive immunization with
monoclonal antibodies against HA2 gp, as well as active
immunization with recombinant vaccinia virus expres-
sing chimeric molecules of HA, improve the recovery
from influenza infection and contribute to a milder
course of infection [28,29]. A recent study showed that
increased immunogenicity of HA2 gp could be achieved
by unmasking of HA2 gp after removing the highly
immunogenic globular head domain of HA1 gp. Headless
HA trimers form the conserved HA stalk domain, on
which HA2 epitopes are more accessible for B cells than
in the native HA. Vaccination of mice with this headless
HA immunogen elicited antibodies cross-reactive with
multiple subtypes of hemagglutinin and provide protec-
tion against lethal influenza virus infection [31].
Hemagglutinin HA1-HA2 connecting region, as well
as N-terminal fusion peptide of HA2, are the broadly
conserved parts of HA, the latter conserved even among
all 16 subtypes of influenza A viruses [1,47,61,64]. Pro-
tective potential of the fusion peptide or HA1-HA2 clea-
vage site of influenza A viruses were investigated by
several groups. They found that mice vaccinated with a
peptide spanning the HA1-HA2 connecting region
exhibited milder illness and fewer deaths upon virus
challenge [64,65].
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sally conserved fusion peptide has attracted interest in
the recent past, as such antibodies are known to inhibit
the HA fusion activity and to reduce virus replication
in vitro and also in vivo [28,30,54,62,63]. Additionally,
passive immunotherapy with Abs reactive with all
strains of influenza A could be an alternative for some
populations at high risk of infection, like infants, the
elderly and the immunocompromised patients, who may
not benefit from active vaccination. Several groups
described the potential of human monoclonal antibodies
against HA2 subunit and its fusion peptide with broad-
spectrum protection as a universal passive immunother-
apeutic agent against seasonal and pandemic influenza
viruses [66-69]. Sui et al. [70] obtained a panel of high-
affinity human antibodies that bind to the highly
conserved pocket in the stem region of hemagglutinin,
comprising part of the fusion peptide and several resi-
dues of the HA1 subunit. These antibodies showed a
broad degree of cross-reactivity. Moreover, it was sug-
gested that the conformational epitope on HA recog-
nized by one of these neutralizing antibodies (F10) is
recalcitrant to the generation of escape mutants [70].
Thus, identification of antibodies against conserved
epitopes of hemagglutinin shows the way for their use
in passive immunotherapy, designing of antivirals and
represents an important step towards development of
cross-protective universal vaccine against influenza virus
that potentially does not require annual adjustment.
4.3 Internal influenza antigens
Nucleoprotein (NP) and matrix protein (M1) of influ-
enza virus are conserved structural influenza antigens,
to which antibody response is induced after natural
infection. These antibodies, however, do not display a
considerable effect on protection against influenza infec-
tion [22]. On the other hand, NP, M1 and other inner
influenza antigens play important role in the cellular
immune response. It was demonstrated that NP- or
M1-specific Th cells could augment protective antibody
response, aiding the B cells to produce antibodies speci-
fic to hemagglutinin [71].
5. Conserved antigens of influenza virus as
inductors of protective cellular immunity
CTL play an important role in the control of influenza
virus infections. They eliminate virus-infected cells, on
which surface they recognize foreign antigens derived
from endogenously expressed viral antigens presented
by MHC class I molecules. Thus, they contribute to the
clearance of the virus from the infected tissue and pre-
vent the spread of viral infection. Although CTL do not
prevent influenza infection, their beneficial effect on the
course of infection was observed after the adoptive
transfer of virus-specific CTL clones to mice, resulting
in direct lysis of infected cells [72-74]. In addition,
depletion of CTL in infected mice led to higher titers of
the virus in lungs, increased mortality and more severe
disease [75]. Depending on their antigen specificity,
CTLs may be subtype-specific or, in case they recognize
the internal antigens, they are broadly cross-reactive
with various influenza A viral strains. Early studies in
mice showed that the majority of influenza-specific
CTLs were reactive across subtypes [76,77], what under-
lines their important role in heterosubtypic immunity.
This high crossreactivity is explained by the antigenically
conserved targets of CTL represented mostly by inner
influenza antigens (e.g. NP, M1 and PB1, PB2) [78-81].
However, some conserved T-cell epitopes were identi-
fied also on variable surface influenza antigens [82-84].
Recent data support the beneficial role of T-cell
response in reducing the severity of infection also in
humans [85-88]. Additionally, cross-reactive CTLs
recognized different subtypes of influenza A virus and
their protective effect was shown also in individuals,
who did not have specific antibodies against a given
influenza virus they were exposed to [89]. Therefore,
vaccination strategies focused on generating T-cell-
mediated immune responses directed towards conserved
epitopes of influenza virus are also considered.
5.1 Conserved influenza virus T-cell epitopes
identification and their vaccine application
T-cell epitopes are intensively studied as an alternative
to the current vaccine strategy based mainly on the
induction of the strain specific virus-neutralizing antibo-
dies. Identification of conserved CTL epitopes shared by
many influenza strains could represent the basis of vac-
cination strategies. This approach would be beneficial in
the case of annual influenza epidemic and a potential
pandemic, when humoral immunity is poorly or not
protective due to the absence of pre-existing antibodies
against emerging strains in the population [90,91].
While CTL mediated immunity is considered to be
weak, epidemiological data indicate induction of cross-
protective immunity in humans, who overcame
influenza infection in the past [85]. It was shown that
memory T-cells against the conserved epitopes confer
protection from the infection with the virus strains of
different subtypes in humans [82,85,86,88,89,92,93].
Studies in mice demonstrated that, similar to the live
influenza vaccine, adenovirus-based vaccine and DNA
immunization induced CTL cross-protective immune
response against infection with multiple influenza A
subtypes [94-98]. The variable rate of cross-reactive
CTL response was achieved also by using adjuvants, or
various formulations and delivery systems with experi-
mental influenza vaccines in preclinical animal studies
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virus-like particles or virosomal vaccines could be suc-
cessfully used for efficient delivery of multiple CTL epi-
topes to the target cells resulting in induction of CTL
response [100,101].
Heterosubtypic immunity mediated by CTLs was
described in naturally infected humans [88,89,102]. It is
developed mainly against conserved epitopes of NP, M1
and NS1 [82,103-106]. Kreijtz et al. showed that virus-
specific CTL developed in humans as a response to
previous exposition to seasonal influenza A viruses of
the H3N2 and H1N1 subtypes displayed considerable
cross-reactivity also with avian influenza viruses
(e.g. A/H5N1) [86]. Thus, it could be supposed that
obtained pre-existing T-cell immunity in humans may
help to decrease the severity of infection during a pan-
demic outbreak in comparison to those individuals, who
lack cross-reactive influenza specific CTL populations
[86,88,107]. Therefore, vaccines based on conserved
CTL epitopes represent a reasonable approach to gener-
ate effective broadly protective cellular immunity against
influenza viruses of various subtypes.
6. Immunodominance of influenza T-cell epitopes
To develop vaccines capable of stimulating effective T-cell
response, it is necessary to understand the factors contri-
buting to the immunodominance of CTL epitopes. During
viral infection, a large number of peptides are generated
by processing of viral proteins in the proteasomes of
infected cells. Only a small fraction of these peptides are
presented by MHC class I molecules and subsequently
recognized by specific CTL. This hierarchy of CTL
response proved in animals [108] and in humans [104] is
called immunodominance. There are several factors,
which contribute to this phenomenon: HLA haplotype
and its binding affinity to individual epitopes, repertoire of
T-cell receptors, processing and presentation of viral pep-
tides and interaction of CTL with antigen-presenting cells
[109,110]. It was shown that efficiency of epitope proces-
sing is one of the dominant factors affecting immunogeni-
city of multi-epitope vaccine [111,112].
The most frequently used models for such immunolo-
gical studies are inbred mice, like B57BL6 (H-2
b)o r
BALB/c (H-2
d) mice. Therefore, T-cell influenza specific
epitopes in inbred mice were studied by many authors.
Comprehensive analysis regarding existing influenza A
epitopes in mice among avian and human influenza
strains was done by Bui et al. [113]. However, not all T-
cell epitopes are equally immunogenic. In inbred mice
B57BL6 (H-2
b), peptides from nucleoprotein
D
bNP366-374 a n df r o mas u b u n i to fv i r a lR N Ap o l y m e r -
ase D
bPA224-233 are immunodominant, while nucleopro-
tein epitope K
dNP147-155 is immunodominant in BALB/
c (H-2
d) mice [84,114-116].
In contrast to inbred mice, the search for CTL epi-
topes suitable for development of CTL epitope-based
vaccine in humans is more complicated [113]. The main
reason is that HLA genes in humans are extremely poly-
morphic. Therefore, the knowledge of HLA restriction
in population, which will be vaccinated, is necessary.
The complexity of HLA molecules could be reduced by
clustering them into sets of molecules that bind largely
overlapping peptides. Such clustering was introduced by
Sette and Sidney in 1999. They defined HLA supertypes
as a set of HLA molecules that have similar peptide
binding motifs and overlapping peptide binding reper-
toires [117]. Nine different supertypes (A1, A2, A3, A24,
B7, B27, B44, B58, B62) were defined on the basis of
their specifity for the main anchor positions of pre-
sented peptides. Later, other three HLA I supertypes
(A26, B8 and B39) were described by Lund et al. [118].
Recent analysis provided an update of HLA I alleles
classification into supertypes and is expected to facilitate
epitope identification and vaccine design studies [119].
An example of most frequently recognized conserved
epitopes of influenza antigens in humans represents
M158-66 CTL epitop, which is restricted by the high pre-
valence allele HLA-A*0201 and could be a promising
vaccine candidate [120]. Computer programs available
today can predict binding epitopes of a given protein for
the most common HLA allele [121,122]. In silico analy-
sis supports the proposition that the T-cell response to
cross-reactive T-cell epitopes induced by vaccination or
seasonal viral exposition may have the capacity to
attenuate the course of influenza infection in the
absence of cross-reactive antibody response [123,124].
The ability to predict the CTL epitope immunogenicity
and recognition patterns of variant epitopes enhances
the probability of the optimal selection of potential tar-
gets of immune response and can be utilized for vaccine
design [93,113,125]. In spite of the differences in various
classification schemes, the concept of HLA supertypes
has been effectively used to characterize and identify
promiscuously recognized T-cell epitopes from a variety
of different disease targets, as are those of hepatitis C
virus [126,127], SARS [128] or HIV [129,130] but also
influenza virus [131].
A critical requirement for CTL epitope-based strategy
is to identify and select promiscuous CTL epitopes that
bind to several alleles of HLA supertypes to reach maxi-
mal population coverage. The utilization of supertype-
restricted epitopes, which bind with significant affinity
to multiple related HLA alleles, provides solution to this
problem [117]. As described before, 80-90% population
coverage can be achieved in most prominent ethnicities
by focusing on only three major HLA class I supertypes
-A1, -A3 and -B7 [132,133]. By including two additional
supertypes (A1, A24), 100% population coverage in all
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HLA class I -A2, -A3 or -B7 supertype-restricted epi-
topes conserved among different viral subtypes of influ-
enza virus were identified, what could be of relevance
for the development of a potential supertype-restricted,
multiepitope CTL-based vaccine protective against any
subtype of influenza virus [82,103,113,134].
7. Conclusion
One of the drawbacks of currently available inactivated
vaccines is the lack of broad cross-protective humoral
and cell-mediated immune response against any influ-
enza virus. Their efficacy is limited due to the genetic
variation of influenza viruses. Therefore, their annual
reformulation is necessary in an attempt to antigenically
match the currently circulating strain for each of the
three vaccine strains or their subunits (HA and NA of
H1N1 and H3N2 of influenza A virus as well as of influ-
enza B virus) from which they are composed. Increasing
amount of information about conserved epitopes of influ-
e n z av i r u s e sb r i n g su sc l o s e r to the development of the
universal vaccine. Such vaccine should contain both, con-
served B-cell epitopes that are important for induction of
cross-protective antibodiesa n dC T Le p i t o p e sf o rt h e
involvement of the cellular arm of the immune response
to the overall protective effect [90]. It was shown that the
pre-existing memory T-cell immunity as defense against
seasonal influenza strains may have the capacity to mod-
erate the course of disease in the case of newly emerging
flu viruses in the absence of cross-reactive antibody
response [86,93,123,124]. It was also shown that it would
be possible to elicit the CTL response simultaneously
directed against multiple supertype-restricted conserved
CTL epitopes [135-139]. This could be relevant for the
development of a potential supertype-restricted multiepi-
tope CTL based vaccine, with the effort to reach wide
population coverage. Even though recent reports support
a beneficial role of T-cell response in reducing human
infections [86-88,124], there are still many questions
regarding the feasibility of designing an effective super-
type-restricted CTL epitope based vaccine in humans. In
addition to CTL epitopes, B-cell epitopes from conserved
influenza antigens that can elicit cross-protective
humoral response should also be considered as a compo-
nent of novel vaccines. Recently, highly cross-reactive
monoclonal antibodies directed against conserved epi-
topes of HA2 subunit, including fusion peptide, were
identified [28,30,66,68-70]. HA2 subunit region as well as
M2 protein are promising candidates for design of vac-
cine constructs aimed at providing broad-spectrum
immunity to influenza viruses [1,28,31,37,45]. Cross-pro-
tective potential of HA2 and eM2 could be increased by
optimization of their delivery and immunogenicity using
vaccine vectors that target multiple Toll-like receptors
for efficient stimulation of innate immunity and subse-
quent enhancement of the adaptive immune response
[41,140]. Conserved B- and T-cell epitopes, thus, could
represent the basis for preparation of universal vaccine
and bring new hope for development of pandemic or uni-
versal influenza vaccine.
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